The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol. 2014;20(1):38-46.   Published online 2014 Mar 26     DOI: https://doi.org/10.3350/cmh.2014.20.1.38
Citations to this article as recorded by Crossref logo
Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment
Mostafa Elhelbawy, Wael Abdel-Razek, Ayman Alsebaey, Mohamed Hashim, Hassan Elshenawy, Imam Waked
European Journal of Gastroenterology & Hepatology.2019; 31(1): 16.     CrossRef
Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
Yi-Hao Yen, Kwong-Ming Kee, Chien-Hung Chen, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Houng Wang, Chao-Hung Hung, Tatsuo Kanda
PLOS ONE.2019; 14(1): e0208858.     CrossRef
Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients
Ayush Jain, Bhupinder Singh Kalra, Siddharth Srivastava, Shalini Chawla
Indian Journal of Gastroenterology.2019; 38(1): 39.     CrossRef
Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
Mary-Anne Doyle, Chrissi Galanakis, Erin Mulvihill, Angela Crawley, Curtis Cooper
Cells.2019; 8(3): 252.     CrossRef
Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
Mary-Anne Doyle, Terry Lee, Joel Singer, Angela Crawley, Marina Klein, Curtis Cooper
Open Forum Infectious Diseases.2019;[Epub]     CrossRef
HCV treatment with direct acting antivirals improves the insulin sensitivity
Ayman Alsebaey, Mostafa Elhelbawy, Wael Abdel-Razek, Mohammed Hashim, Hassan Elshenawy, Imam Waked
Expert Review of Anti-infective Therapy.2019; 17(9): 749.     CrossRef
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
Goki Suda, Jun Ito, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Munenori Okamoto, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, Takashi Meguro, Masatsugu Ohara, Naoki Kawagishi, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Y
Hepatology Research.2018; 48(3): E146.     CrossRef
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi
Gut and Liver.2018; 12(2): 201.     CrossRef
Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment
Gilmar de Souza Lacerda, Thalia Medeiros, Natalia Fonseca do Rosário, Regina Helena Saramago Peralta, Mauro Jorge Cabral-Castro, Eliane Bordalo Cathalá Esberard, Thaís Guaraná de Andrade, Analúcia Rampazzo Xavier, Andrea Alice Silva
Clinical Biochemistry.2018; 60: 17.     CrossRef
Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients
Junaid Beig, David Orr, Barry Harrison, Edward Gane
Liver Transplantation.2018; 24(8): 1031.     CrossRef
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Muts
PLOS ONE.2018; 13(12): e0209615.     CrossRef
Hepatitis C virus and atherosclerosis: A legacy after virologic cure?
M.F. Bassendine, S.U. Nielsen, S.H. Bridge, D.J. Felmlee, D.A. Sheridan, C.J. Packard, R.D. Neely
Clinics and Research in Hepatology and Gastroenterology.2017; 41(1): 25.     CrossRef
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
Anne-Claire Desbois, Patrice Cacoub
World Journal of Gastroenterology.2017; 23(9): 1697.     CrossRef
Endemic hepatitis B and C virus areas are associated with lower prevalence of hyperlipidemia: Ecological and cross-sectional studies
Chao-Tung Chen, Wei-Cheng Huang, Jing-Houng Wang, Chuan-Mo Lee, Chao-Hung Hung, Lin-San Tsai, Shu-Chuan Chen, Sheng-Che Lin, Sheng-Nan Lu, Kwong-Ming Kee
Advances in Digestive Medicine.2017; 4(2): 54.     CrossRef
Diabetes and Glucose Metabolism in Thalassemia Major: An Update
Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, Alessia Pepe, Christos Kattamis, Mohamed El Kholy, Mohamed Yassin
Expert Review of Hematology.2016; 9(4): 401.     CrossRef
Change in insulin resistance according to virological response during antiviral treatment for hepatitis C virus infection
Cheng-Hao Tseng, Yao-Chun Hsu, Chi-Yang Chang, Chih-Wen Lin, Jaw-Town Lin, Lein-Ray Mo
Advances in Digestive Medicine.2016; 3(2): 43.     CrossRef
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir
Sebastian Bernuth, Eray Yagmur, Detlef Schuppan, Martin F. Sprinzl, Anca Zimmermann, Arno Schad, Jens M. Kittner, Veronika Weyer, Johanna Knapstein, Jörn M. Schattenberg, Marcus A. Wörns, Peter R. Galle, Tim Zimmermann
Digestive and Liver Disease.2016; 48(3): 291.     CrossRef
Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes
Lucivalda Pereira Magalhães Oliveira, Rosangela Passos de Jesus, Ramona Souza Silva Baqueiro Boulhosa, Thiago Onofre, Carlos Mauricio Cardeal Mendes, Leonardo Vinhas, Dan Linetzky Waitzberg, Denise Carneiro Lemaire, Lourianne N. Cavalcante, Andre Castro L
Journal of the American College of Nutrition.2016; 35(5): 436.     CrossRef
Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
Magnus Hedenstierna, Ali Nangarhari, Ola Weiland, Soo Aleman
Clinical Infectious Diseases.2016; 63(6): 723.     CrossRef
Genotype specific peripheral lipid profile changes with hepatitis C therapy
Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam
World Journal of Gastroenterology.2016; 22(46): 10226.     CrossRef
Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
Adeel A. Butt, Peng Yan, Tracey G. Simon, Raymond T. Chung, Abdul-Badi Abou-Samra
BMC Infectious Diseases.2015;[Epub]     CrossRef
A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients
Sadia Qamar Arain, Farah Naz Talpur, Naseem Aslam Channa
Lipids in Health and Disease.2015;[Epub]     CrossRef
Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
Shao Qing, Dong Ji, Bing Li, Fan Li, Yudong Wang, Xioaxia Niu, Binfang Ling, Yuhua Meng, George Lau, Guofeng Chen
Annals of Saudi Medicine.2015; 35(4): 293.     CrossRef
Liver steatosis in hepatitis C patients
Emilio González-Reimers
World Journal of Hepatology.2015; 7(10): 1337.     CrossRef